Hostname: page-component-76d6cb85b7-pn7tm Total loading time: 0 Render date: 2026-07-15T17:12:28.734Z Has data issue: false hasContentIssue false
  • English
  • Français

Acid Metabolites from Monoamines in Cerebrospinal Fluid of Chronic Schizophrenics

Published online by Cambridge University Press:  29 January 2018

Torgny Persson  and
Björn-Erik Roos
Torgny Persson
Affiliation:
Psychiatric Research Centre, St. Jörgen Hospital, Lillhágen Department of Pharmacology, University of Göteborg, Sweden
Björn-Erik Roos
Affiliation:
Psychiatric Research Centre, St. Jörgen Hospital, Lillhágen Department of Pharmacology, University of Göteborg, Sweden
Get access Rights & Permissions [Opens in a new window]

Extract

Psychotropic drugs used in mental depressions or acute psychoses have been shown to interfere with monoaminergic transmission in the brain. Since it is impossible to study the metabolism of these monoamines directly in the human brain, many studies have been made on the urinary excretion of these amines and their metabolites in various mental conditions. However, few conclusive results have been obtained, because only a very small part of the urinary monoamines and their metabolites derive from the central nervous system.

Information

Type
Biochemical and Metabolic Studies
Information
The British Journal of Psychiatry , Volume 115 , Issue 518 , January 1969 , pp. 95 - 98
Copyright
Copyright © Royal College of Psychiatrists, 1969 

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

Article purchase

Temporarily unavailable

References

1 Carlsson, A., Falck, B., and Hillarp, N.-Å. (1962). “Cellular localization of brain monoamines.” Actaphysiol. Scand., 56, Suppl. 196, 1–28.Google Scholar
2 Despopoulos, A., and Weissbach, H. (1957). “Renal metabolism of 5-hydroxyindole acetic acid.” Am. J. Physiol., 189, 548–550.Google Scholar
3 Ashcroft, G. W., and Sharman, D. F. (1960). “5-Hydroxyindoles in human cerebrospinal fluids.” Nature, Lond., 186, 1050.Google Scholar
4 Roos, B.-E. (1963). “The effect of monoamine oxidase inhibitors on the level of 5-hydroxyindole acetic acid in human cerebrospinal fluid.” Life Sci., 2, 1–4.Google Scholar
5 Dencker, S. J., Malm, U., Roos, B.-E., and Werdinius, B. (1966). “Acid monoamine metabolites in the cerebrospinal fluid in mental depression and mania.” J. Neurochem., 13, 1545–1548.Google Scholar
6 Ashcroft, G. W., Crawford, T. B. B., Eccleston, D., Sharman, D. F., MacDougall, E. J., Stanton, J. B., and Binns, J. K. (1966). “5-Hydroxyindole compounds in the cerebrospinal fluid of patients with psychiatric or neurological diseases.” Lancet, ii, 1049–1052.Google Scholar
7 Andén, N.-E., Roos, B.-E., and Werdinius, B. (1964). “Effects of chlorpromazine, haloperidol and reserpine on the levels of phenolic acids in rabbit corpus striatum.” Life Sci., 3, 149.Google Scholar
8 Mayer-Gross, W., Slater, E., and Roth, M. (1960). Clinical Psychiatry. Second edition. London.Google Scholar
9 Andén, N.-E., Roos, B.-E., and Werdinius, B. (1963). “On the occurrence of homovanillic acid in brain and cerebrospinal fluid and its determination by a fluorimetric method.” Life Sci., 7, 448–458.Google Scholar
10 Johansson, B., and Roos, B.-E. (1965). “Acid monoamine metabolites in the cerebrospinal fluid of patients with Parkinson's syndrome.” Proc. 8th Int. Congr. of Neurol. Vienna, 4/1, 141–144.Google Scholar
11 Johansson, B., and Roos, B.-E. (1967). “5-Hydroxyindole acetic acid and homovanillic acid levels in the cerebrospinal fluid of healthy volunteers and patients with Parkinson's syndrome.” Life Sci., 6, 1449–1454.Google Scholar
12 Bliss, C. I. (1967). Statistics in Biology. Vol. I. McGraw-Hill Book Co., 154, 239–240.Google Scholar
13 Bernheimer, H., Birkmayer, W., and Hornykiewicz, O. (1966). “Homovanillinsäure im Liquor Cerebrospinalis: Untersuchungen beim Parkinson-Syndrom und anderen Erkrankungen des ZNS.” Wien. Klin. Wschr., 23, 417–419.Google Scholar
14 Andén, N.-E., Corrodi, H., Fuxe, K., and Hökfeldt, T. (1967). “Increased impulse flow in bulbospinal noradrenaline neurons by catecholamine receptor blocking agents.” Eur. J. Pharm., 2, 59–64.Google Scholar

This journal is not currently accepting new eletters.

eLetters

No eLetters have been published for this article.